Form 4: Predictive Oncology Interim CFO Granted 97,000 RSUs

Predictive Oncology's Interim CFO, Joshua Blacher, was granted 97,000 restricted stock units, which are scheduled to vest on October 31, 2025.

Summary

• Joshua Blacher, Interim CFO of Predictive Oncology Inc. (POAI), was granted 97,000 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for the acquisition of these RSUs is September 9, 2025.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest in full on October 31, 2025, contingent upon Mr. Blacher's continued service through that date.
• The acquisition price for these RSUs was $0.00 per share, which is typical for such grants.
• Following this reported transaction, Mr. Blacher will beneficially own 97,000 shares directly.

Sentiment

Score: 6

Explanation: The grant of RSUs to a key executive is a moderately positive event, as it aligns management's interests with shareholders and serves as a retention tool. It is a routine compensation matter and not indicative of significant operational changes.

Positives

• The grant of restricted stock units to the Interim CFO aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This type of equity compensation is a standard practice to incentivize key executives for long-term performance and retention.

Negatives

• The issuance of new shares upon vesting of RSUs will result in a minor dilution of existing shareholders' ownership, though the amount is relatively small in this instance.

Future Outlook

The restricted stock units are set to vest in full on October 31, 2025, provided the Interim CFO continues his service with the company until that date.

Industry Context

The grant of restricted stock units to an executive is a common form of equity compensation across various industries, particularly in biotechnology and technology sectors, aimed at retaining talent and aligning executive incentives with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to an executive is a standard component of executive compensation packages across publicly traded companies, comparable to practices at peers in the biotechnology and oncology sectors.
• The vesting schedule, tied to continued service, is a typical mechanism used to promote executive retention and long-term commitment, consistent with industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Experience minor dilution upon vesting of the RSUs, but benefit from increased alignment of executive incentives with long-term company performance.
• Employees (specifically Joshua Blacher): Receive equity compensation, which serves as an incentive for continued service and performance.

Next Steps

• The restricted stock units are scheduled to vest on October 31, 2025, upon which the shares will be issued to Mr. Blacher.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to an executive as part of their compensation. While it aligns management interests, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and await more comprehensive financial or strategic updates.

Keywords

Predictive Oncology, POAI, Joshua Blacher, Interim CFO, Restricted Stock Units, RSUs, Executive Compensation, Insider Transaction, Equity Grant